These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24618213)

  • 21. Altered plasticity of the human motor cortex in Parkinson's disease.
    Ueki Y; Mima T; Kotb MA; Sawada H; Saiki H; Ikeda A; Begum T; Reza F; Nagamine T; Fukuyama H
    Ann Neurol; 2006 Jan; 59(1):60-71. PubMed ID: 16240372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
    Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
    Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of dopamine in motor cortex plasticity in Parkinson's disease.
    Udupa K; Chen R
    Mov Disord; 2016 Jan; 31(1):43. PubMed ID: 26685873
    [No Abstract]   [Full Text] [Related]  

  • 24. TMS-assisted neurophysiological profiling of the dopamine receptor agonist cabergoline in human motor cortex.
    Korchounov A; Ilić TV; Ziemann U
    J Neural Transm (Vienna); 2007 Feb; 114(2):223-9. PubMed ID: 16868794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasticity of the motor cortex in Parkinson's disease patients on and off therapy.
    Bagnato S; Agostino R; Modugno N; Quartarone A; Berardelli A
    Mov Disord; 2006 May; 21(5):639-45. PubMed ID: 16353175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in cortical excitability during paired associative stimulation in Parkinson's disease patients and healthy subjects.
    Kačar A; Milanović SD; Filipović SR; Ljubisavljević MR
    Neurosci Res; 2017 Nov; 124():51-56. PubMed ID: 28606723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine.
    Rascol OJ; Sabatini U; Chollet F; Montastruc JL; Marc-Vergnes JP; Rascol A
    Adv Neurol; 1993; 60():419-21. PubMed ID: 8420165
    [No Abstract]   [Full Text] [Related]  

  • 29. Modulation of corticomotor excitability after maximal or sustainable-rate repetitive finger movement is impaired in Parkinson's disease and is reversed by levodopa.
    Teo WP; Rodrigues JP; Mastaglia FL; Thickbroom GW
    Clin Neurophysiol; 2014 Mar; 125(3):562-8. PubMed ID: 24095151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dysfunctional and compensatory synaptic plasticity in Parkinson's disease.
    Schroll H; Vitay J; Hamker FH
    Eur J Neurosci; 2014 Feb; 39(4):688-702. PubMed ID: 24313650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Boosting focally-induced brain plasticity by dopamine.
    Kuo MF; Paulus W; Nitsche MA
    Cereb Cortex; 2008 Mar; 18(3):648-51. PubMed ID: 17591596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of neuroplasticity in dopaminergic therapy for Parkinson disease.
    Zhuang X; Mazzoni P; Kang UJ
    Nat Rev Neurol; 2013 May; 9(5):248-56. PubMed ID: 23588357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-homogeneous effect of levodopa on inhibitory circuits in Parkinson's disease and dyskinesia.
    Barbin L; Leux C; Sauleau P; Meyniel C; Nguyen JM; Pereon Y; Damier P
    Parkinsonism Relat Disord; 2013 Feb; 19(2):165-70. PubMed ID: 23000298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of L-dopa in Parkinson's disease as revealed by neurophysiological studies of motor and sensory functions.
    Suppa A; Bologna M; Conte A; Berardelli A; Fabbrini G
    Expert Rev Neurother; 2017 Feb; 17(2):181-192. PubMed ID: 27477028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Theta burst stimulation over the supplementary motor area in Parkinson's disease.
    Eggers C; Günther M; Rothwell J; Timmermann L; Ruge D
    J Neurol; 2015 Feb; 262(2):357-64. PubMed ID: 25385053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease.
    Herz DM; Siebner HR; Hulme OJ; Florin E; Christensen MS; Timmermann L
    Neuroimage; 2014 Apr; 90():15-23. PubMed ID: 24269570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mirror movements in Parkinson's disease: effect of dopaminergic drugs.
    Espay AJ; Morgante F; Gunraj C; Chen R; Lang AE
    J Neurol Neurosurg Psychiatry; 2006 Oct; 77(10):1194-5. PubMed ID: 16980659
    [No Abstract]   [Full Text] [Related]  

  • 38. Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia.
    Wang Q; Zhang W
    Front Neural Circuits; 2016; 10():105. PubMed ID: 28066191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of LTP-like plasticity in primary motor cortex in Parkinson's disease.
    Suppa A; Marsili L; Belvisi D; Conte A; Iezzi E; Modugno N; Fabbrini G; Berardelli A
    Exp Neurol; 2011 Feb; 227(2):296-301. PubMed ID: 21145888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.